Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 13, 2005 Stephen D. Simpson	Waiting for Sanofi's Next Act Sanofi-Aventis' first-quarter numbers were good. Will they soon be better? Though the stock is not the greatest idea for highly income-oriented investors, the growth-at-a-reasonable-price crowd might want to investigate further.
The Motley Fool July 23, 2009 Brian Orelli	The Slowly Wilting Lilly Nothing can save this drug company.
The Motley Fool May 5, 2006 Stephen D. Simpson	Sanofi-Aventis Waits It Out This is the hurry up-and-wait part of the French pharma's story, with product approvals on the way soon, investors hope.
The Motley Fool April 30, 2008 Brian Lawler	Alexza Advances 2 More Drugs The pharmaceutical company's compounds keep zipping through clinical trials.
The Motley Fool August 30, 2010 Brian Orelli	Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help.
The Motley Fool February 14, 2005 Stephen D. Simpson	Glaxo Stays Above the Fray The British drugmaker looks to regain momentum this year. Investors who are comfortable with the general industry risks and are looking for a relatively "clean" pharmaceutical company should do some research on Glaxo shares.
The Motley Fool February 25, 2009 Brian Orelli	Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials.
The Motley Fool April 27, 2006 Stephen D. Simpson	Glaxo's Story Still Worth Reading A good pipeline could keep GlaxoSmithKline's already-impressive shares rolling.
The Motley Fool May 5, 2009 Robert Steyer	Sanofi-Aventis' To-Do List The French drugmaker seeks acquisitions to reinforce and expand its business geographically and scientifically.
The Motley Fool April 30, 2010 Brian Orelli	Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter.
The Motley Fool January 26, 2005 Stephen D. Simpson	Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation.
The Motley Fool July 20, 2007 Brian Orelli	Arena Keeps Burning the Cash The pipeline drugs being developed by Arena Pharmaceuticals hold promise, but it will be a while before, or if, the company shows a profit.
The Motley Fool May 29, 2009 Brian Orelli	This Company Is Hot and Going Places Pharma company sanofi-aventis licenses a program, including two phase 1 compounds from Exelixis.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool December 12, 2007 Brian Orelli	What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010.
The Motley Fool December 11, 2006 Brian Lawler	Weighing In on Sanofi's Acomplia With the future of Sanofi's two top drugs in the hands of the courts, plus any Acomplia approval subject to the whims of the FDA, investors should wait on the sidelines until these judicial and regulatory decisions have been made.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool March 14, 2008 Brian Orelli	Weighing In on Obesity Drugs Could investing in drugmakers that produce weight-loss drugs help fatten your wallet?
The Motley Fool April 28, 2011 Brian Orelli	1 Year to P-Day, Bristol-Myers Squibb Looks Just Fine New drugs should help cushion the fall from the loss of Plavix.
The Motley Fool October 3, 2008 Brian Orelli	Merck Can't Fight the Munchies The pharma gives up on its anti-obesity drug.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool June 21, 2007 Brian Orelli	Dumpster Diving in Pfizer's Trash Investors are probably overreacting to Pfizer's decision, but only time -- and clinical trials -- will tell.
The Motley Fool November 1, 2006 Brian Lawler	Le Generic Excuse for Sanofi Even with its massive pipeline, there may be problems ahead for Sanofi. Its two top drugs are exposed to generic threats as Sanofi fights in court to keep generic competitiors out of those markets. Investors, take note.
The Motley Fool October 30, 2009 Brian Orelli	Shrugging Off the Side Effects Sanofi-aventis is looking good, but still faces the patent protection loss of Lovenox.
The Motley Fool February 14, 2008 Brian Lawler	Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops.
The Motley Fool December 14, 2005 Stephen D. Simpson	Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster.
The Motley Fool February 29, 2008 Brian Lawler	Nektar Squeezing Along Nektar Therapeutics finishes a topsy-turvy 2007, and gives some good guidance for upcoming year.
The Motley Fool May 4, 2006 Stephen D. Simpson	AstraZeneca Snuffs Out Galida Will any of the new dual-PPAR drugs make it to the market? Here's another good reminder for pharmaceutical and biotech investors that you shouldn't count your chickens until the FDA has let them hatch.
The Motley Fool January 31, 2007 Brian Lawler	Lilly Floats Atop Rivals The large-cap pharma posts slow, steady growth. Investors, take note.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool September 6, 2011 Brian Orelli	Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool April 2, 2007 Brian Lawler	A Good Week for Alexza The pharma reports positive clinical trial results. Investors, take note.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool September 25, 2007 Brian Orelli	No Drugs, No Rally Sonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes.
The Motley Fool June 27, 2008 Brian Lawler	Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal.
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
The Motley Fool November 17, 2009 Dave Mock	A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst.
The Motley Fool February 2, 2006 Stephen D. Simpson	AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here.
The Motley Fool January 31, 2006 Stephen D. Simpson	Wyeth: Waiting on the Pipeline While Wyeth's growth today is modest, the late-stage pipeline could pay off. Investors, take note.
The Motley Fool February 10, 2009 Robert Steyer	Rx for a Drug Deal? Will circumstance and psychology prod Sanofi-Aventis into a big acquisition?
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
The Motley Fool April 28, 2008 Brian Lawler	Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results.
The Motley Fool December 5, 2008 Brian Orelli	Good Luck in 2010, Merck It's not just one problem for Merck, but a whole series of issues that have turned the company into a heap of stale drugs.
The Motley Fool October 18, 2005 Stephen D. Simpson	More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note.
The Motley Fool June 9, 2010 Brian Orelli	The Drug Passed, but the Stock Fell? Regeneron only bats .500.
The Motley Fool November 1, 2004 Brian Gorman	Bristol-Myers Stays the Course The pharma remains downbeat on its outlook through 2006, but two promising compounds could lift the company's fortunes.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool February 20, 2007 Brian Lawler	Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead.
The Motley Fool September 5, 2007 Billy Fisher	Lilly's Pipeline Continues to Produce Another schizophrenia drug from the company shows promise in a clinical trial, prompting the company to plan additional trials. This is the latest good news in what has been a good year for Lilly.